The phrase "a decrease in intestinal" is correct and usable in written English.
It can be used in contexts discussing health, biology, or medical conditions related to the intestines.
Example: "The study found a decrease in intestinal absorption of nutrients in patients with the condition."
Alternatives: "a reduction in intestinal" or "a decline in intestinal".
Taken together, FXR ligands counteract hepatic inflammation at several levels: directly via interaction with inflammatory pathways in hepatocytes as well as in non-parenchymal hepatic cells and by reducing release of inflammatory mediators from the intestine via a decrease in intestinal permeability and bacterial translocation.
Using similar mouse models, moderate or high overexpression of HIF-1α leads to a decrease in intestinal damage in a colitis model, as expected [18].
Surprisingly, inflammation was not reduced despite a decrease in intestinal permeability and significant inhibition of Salmonella translocation.
The extract (1000 mg/kg) produced a decrease in intestinal transit comparable to atropine (5mg/kg), and significantly (p<0.01) inhibited castor oil-induced enteropooling.
Similar to the Asbt null model, there is a decrease in intestinal lipid absorption due to a reduction in the bile acid pool size.
The authors suggested that this was mainly due to a decrease in intestinal cholesterol absorption and/or reduction of hepatic cholesterol synthesis.
We have also shown that the processed 35-kDa form of HAP induces a dose-dependent hemorrhagic response in the RIL assay, a decrease in the intestinal short circuit current (Isc) in an Ussing chamber, and a cell rounding effect on HeLa cells.
In addition, obese-prone rats treated with HF-diet exhibit an upregulation of TLR4 in the gut wall and a decrease in the intestinal alkaline phosphatase activity.
In a study by Kuhnert (2004) the antagonism of Wnt signalling resulted in a marked decrease in intestinal epithelial proliferation and a degeneration of intestinal architechture [ 45].
However, there was a 50% decrease in intestinal cell proliferation and a 20% decrease in cell migration associated with the high genistein dose.
The IL10 knockout mouse is felt to be an established model of chronic inflammatory injury and remodelling in the gastrointestinal tract, and animals treated with this antiangiogenic compound showed improvement in their disease activity index, an improved histological colitis score with a parallel decrease in intestinal microvessel density.
